首页> 外文期刊>Expert review of vaccines >Live attenuated vaccine: The first clinically approved dengue vaccine?
【24h】

Live attenuated vaccine: The first clinically approved dengue vaccine?

机译:减毒活疫苗:首个临床批准的登革热疫苗?

获取原文
获取原文并翻译 | 示例
           

摘要

Dengue virus (DENV) is the most prevalent mosquito-borne viral pathogen in humans. There are 390 million human infections each year, with 96 million infections exhibiting disease symptoms. Currently, there is no clinically approved vaccine and antiviral for DENV. The four serotypes of DENV (DENV-1, -2, -3 and -4) have 25-40% variation at the amino acid level. Such variation has posed challenges for the development of a tetravalent vaccine and therapeutics.
机译:登革热病毒(DENV)是人类中最普遍的蚊媒病毒病原体。每年有3.9亿例人类感染,其中9600万例具有疾病症状。当前,没有针对DENV的临床批准的疫苗和抗病毒药。 DENV的四种血清型(DENV-1,-2,-3和-4)在氨基酸水平上有25-40%的差异。这种变化对四价疫苗和治疗剂的开发提出了挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号